Pfizer (PFE) Tops Q3 EPS by 44c, Beats on Revenue; Offers FY24 Guidance

Pfizer (NYSE: PFE) reported Q3 EPS of $1.06, $0.44 better than the analyst estimate of $0.62. Revenue for the quarter came in at $17.7 billion versus the consensus estimate of $14.92 billion.

GUIDANCE:

Pfizer sees FY2024 EPS of $2.75-$2.95, versus the consensus of $2.65. Pfizer sees FY2024 revenue of $61-64 billion, versus the consensus of $61.2 billion.

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• DocGo (DCGO) Misses Q2 EPS by 6c; Offers Guidance
• Brookfield offers A$4.75/sh for Reliance Worldwide - Bloomberg
• Kaiser Aluminum names Fred Stephan as CEO, effective November 2026